Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD)

NCT00473928 is registered in ClinicalTrials.gov with Potentia Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00473928
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00473928 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD)
Lead sponsor
Potentia Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2007
Completion date
February 28, 2010
Enrollment
27 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration